News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
866,113 Results
Type
Article (87703)
Company Profile (824)
Press Release (777573)
Multimedia
Podcasts (184)
Webinars (28)
Section
Business (233158)
Career Advice (4142)
Deals (39827)
Drug Delivery (143)
Drug Development (91337)
Employer Resources (203)
FDA (18341)
Job Trends (17414)
News (397654)
Policy (39945)
Tag
Academia (3006)
Academic (2)
Accelerated approval (24)
Adcomms (35)
Allergies (134)
Alliances (56980)
ALS (162)
Alzheimer's disease (1749)
Antibody-drug conjugate (ADC) (298)
Approvals (18423)
Artificial intelligence (569)
Autoimmune disease (123)
Automation (33)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (182)
Biotechnology (487)
Bladder cancer (148)
Brain cancer (59)
Breast cancer (568)
Cancer (4499)
Cardiovascular disease (401)
Career advice (3564)
Career pathing (39)
CAR-T (273)
CDC (59)
Cell therapy (751)
Cervical cancer (35)
Clinical research (76286)
Collaboration (1551)
Company closure (5)
Compensation (1037)
Complete response letters (64)
COVID-19 (2973)
CRISPR (92)
C-suite (716)
Cystic fibrosis (145)
Data (5523)
Decentralized trials (2)
Denatured (67)
Depression (129)
Diabetes (488)
Diagnostics (7153)
Digital health (42)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (266)
Drug pricing (205)
Drug shortages (36)
Duchenne muscular dystrophy (218)
Earnings (99864)
Editorial (59)
Employer branding (25)
Employer resources (173)
Events (134309)
Executive appointments (1008)
FDA (21120)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (21)
Funding (1406)
Gene editing (199)
Generative AI (57)
Gene therapy (604)
GLP-1 (1073)
Government (5415)
Grass and pollen (8)
Guidances (379)
Healthcare (20941)
HIV (54)
Huntington's disease (44)
IgA nephropathy (79)
Immunology and inflammation (269)
Immuno-oncology (30)
Indications (69)
Infectious disease (3238)
Inflammatory bowel disease (196)
Inflation Reduction Act (16)
Influenza (110)
Intellectual property (212)
Interviews (816)
IPO (17940)
IRA (59)
Job creations (5198)
Job search strategy (2866)
Kidney cancer (17)
Labor market (88)
Layoffs (651)
Leadership (38)
Legal (10153)
Liver cancer (94)
Longevity (14)
Lung cancer (635)
Lymphoma (325)
Machine learning (37)
Management (66)
Manufacturing (717)
MASH (164)
Medical device (14957)
Medtech (14995)
Mergers & acquisitions (22854)
Metabolic disorders (1265)
Multiple sclerosis (148)
NASH (23)
Neurodegenerative disease (310)
Neuropsychiatric disorders (81)
Neuroscience (2917)
NextGen: Class of 2025 (7703)
Non-profit (5100)
Now hiring (61)
Obesity (601)
Opinion (324)
Ovarian cancer (149)
Pain (181)
Pancreatic cancer (195)
Parkinson's disease (263)
Partnered (33)
Patents (457)
Patient recruitment (380)
Peanut (58)
People (66573)
Pharmaceutical (145)
Pharmacy benefit managers (30)
Phase I (23537)
Phase II (33105)
Phase III (24956)
Pipeline (3617)
Policy (317)
Postmarket research (3554)
Preclinical (10634)
Press Release (72)
Prostate cancer (226)
Psychedelics (52)
Radiopharmaceuticals (284)
Rare diseases (766)
Real estate (7432)
Recruiting (80)
Regulatory (28443)
Reports (65)
Research institute (2712)
Resumes & cover letters (651)
Rett syndrome (22)
RNA editing (16)
RSV (81)
Schizophrenia (145)
Series A (227)
Series B (174)
Service/supplier (30)
Sickle cell disease (90)
Special edition (26)
Spinal muscular atrophy (174)
Sponsored (46)
Startups (4324)
State (2)
Stomach cancer (19)
Supply chain (106)
Tariffs (97)
The Weekly (115)
Vaccines (1092)
Venture capital (76)
Weight loss (422)
Women's health (73)
Worklife (21)
Date
Today (12)
Last 7 days (641)
Last 30 days (2698)
Last 365 days (33298)
2025 (31649)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1288)
Alabama (83)
Alaska (7)
Arizona (322)
Arkansas (14)
Asia (51238)
Australia (9008)
California (10623)
Canada (3119)
China (1013)
Colorado (448)
Connecticut (474)
Delaware (315)
Europe (117829)
Florida (1559)
Georgia (343)
Hawaii (3)
Idaho (68)
Illinois (880)
India (61)
Indiana (510)
Iowa (22)
Japan (363)
Kansas (130)
Kentucky (41)
Louisiana (28)
Maine (81)
Maryland (1387)
Massachusetts (7883)
Michigan (336)
Minnesota (615)
Mississippi (6)
Missouri (132)
Montana (34)
Nebraska (27)
Nevada (116)
New Hampshire (81)
New Jersey (2912)
New Mexico (32)
New York (2849)
North Carolina (1521)
North Dakota (10)
Northern California (4975)
Ohio (322)
Oklahoma (22)
Oregon (52)
Pennsylvania (2164)
Puerto Rico (20)
Rhode Island (47)
South America (1656)
South Carolina (60)
South Dakota (1)
Southern California (4084)
Tennessee (164)
Texas (1662)
United States (38726)
Utah (319)
Vermont (1)
Virginia (269)
Washington D.C. (85)
Washington State (896)
West Virginia (4)
Wisconsin (109)
Wyoming (2)
There are 866,113 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
December 8, 2025
·
12 min read
Press Releases
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
December 8, 2025
·
6 min read
Press Releases
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
December 8, 2025
·
12 min read
Press Releases
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 8, 2025
·
19 min read
Press Releases
Freenome and Perceptive Capital Solutions Corp Announce Business Combination Agreement to Create a Publicly Listed Company Transforming Blood-Based Multi-Cancer Detection through an AI/ML-Enabled Multiomics Platform
December 8, 2025
·
13 min read
Press Releases
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer
December 8, 2025
·
7 min read
Press Releases
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
December 8, 2025
·
4 min read
Press Releases
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
December 8, 2025
·
7 min read
FDA
Rare Disease Leaders Call for Regulatory Consistency After Chaotic Year
As the FDA unveils a parade of initiatives aimed at accelerating drug development for rare diseases, experts appeal for a consistent approval process that will support and further catalyze momentum.
December 8, 2025
·
8 min read
·
Heather McKenzie
Sponsored
Accelerating timelines and reducing cost in early clinical drug development with ICON’s Accelerated Pharmaceutical Solutions
Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced formulation design, real-time dose flexibility, and cutting-edge CMC expertise to transform complexity into clarity. By uniting science, technology, and strategy, biotechs can move faster, smarter, and with confidence—turning obstacles into opportunities for breakthrough success.
December 8, 2025
·
5 min read
·
Arjen Akkerman
1 of 86,612
Next
